7.12.2010 - Reata Pharmaceuticals Completes $78 Million Equity Financing for Second Pivotal Trial of Bardoxolone Methyl
	Reata Pharmaceuticals, Inc. has completed a $78 million equity financing led by existing investors CPMG, Inc. and Novo A/S. This financing brings the total raised by the Company to $180 million since inception.
	6.9.2010 - Reata to Present at Jefferies 2010 Global Life Sciences Conference on 6/10/2010 at 1 P.M. EST
	The presentation will focus primarily on the company’s lead program, bardoxolone methyl, a first-in-class Antioxidant Inflammation Modulator (AIM). This agent is in pivotal studies in patients with chronic kidney disease and type 2 diabetes.
	4.18.2010 - Reata Announces Presentation of Bardoxolone Methyl Data at the National Kidney Foundation (NKF) 2010 Spring Clinical Meetings
	Reata Pharmaceuticals, Inc. announces that data regarding bardoxolone methyl, the company’s lead molecule currently in late-stage clinical trials in patients with chronic kidney disease (CKD) and type 2 diabetes, was presented in the following posters at the National Kidney Foundation (NKF) 2010 Spring Clinical Meetings.
	1.8.2010 - Reata to Present at J.P. Morgan Conference on 1/14 at 1:00 PST
	Reata Pharmaceuticals, Inc. announces that J. Warren Huff, Chief Executive Officer and President, will present a company overview at the 28th Annual J.P. Morgan Healthcare Conference. The presentation will be held at 1:00 p.m. PST in the Elizabethan C/D Room at the Westin St. Francis Hotel in San Francisco, CA.
	1.7.2010 - Reata Pharmaceuticals Licenses CKD Drug to Kyowa Hakko Kirin for Asian Markets
	Reata Pharmaceuticals, Inc. (Reata) and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) announced today that they have entered into a licensing agreement that provides Kyowa Hakko Kirin with the exclusive rights to develop and commercialize Reata's lead compound, bardoxolone methyl (bardoxolone), in Japan and other selected Asian markets. Under the terms of the agreement, Reata is eligible to receive up to $272 million in up-front fees and milestone payments, in addition to double-digit royalties.

	12.3.2009 - Reata Announces Recent Conferences Participation
	Reata Pharmaceuticals, Inc. announces the company’s participation in three recent investor conferences: The 8th Annual BIO Investor Forum, the Oppenheimer 20th Annual Healthcare Conference, and the Lazard Capital Markets 6th Annual Healthcare Conference.
	11.1.2009 - Reata Presents Bardoxolone Methyl Data at the American Society of Nephrology Renal Week 2009
	Reata Pharmaceuticals, Inc. today announces the company's multiple presentations at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition, which took place from October 27th through November 1st in San Diego, CA.
	9.4.2009 - Reata to Present at Thomas Weisel Partners 2009 Healthcare Conference
	Reata Pharmaceuticals, Inc. announces that the company's Vice President of Finance, Jason Wilson, will be presenting a company overview on Wednesday, September 9, 2009 at the Thomas Weisel Partners 2009 Healthcare Conference at 3:15 p.m., EST. The event will be held from September 9th through the 11th at the Four Seasons Hotel in Boston, MA.
	8.5.2009 - Reata Presents at BMO Capital Markets Conference
	IRVING, TX - August 5, 2009 -- Reata Pharmaceuticals, Inc. announces that its CEO, Warren Huff, presented a company overview on Wednesday, August 5, 2009 at the BMO Capital Markets "9th Annual Focus on Healthcare Conference" at 2:15 p.m., EST. The event was held at the Millennium Broadway Hotel in New York, New York.
	6.6.2009 - Reata Presents Promising Data on Bardoxolone at American Diabetes Association Annual Scientific Meeting; Phase II Results Demonstrate Significant Increase in Glomerular Filtration Rate in Diabetic Patients with Advanced Chronic Kidney Disease
	Reata Pharmaceuticals, Inc. today announced that results of a Phase II clinical trial of bardoxolone, its lead antioxidant inflammation modulator (AIM), conducted in 60 diabetic patients with advanced chronic kidney disease (CKD) will be the subject of two oral presentations at the 69th annual meeting of the American Diabetes Association. The final data from the study demonstrated that patients treated with bardoxolone experienced a greater than 20 percent increase (p<0.0001) over baseline in their estimated glomerular filtration rate (GFR), a measure of the kidney's filtration capacity and the primary endpoint of the study. CKD is a progressive and incurable disease, and currently approved treatments only modestly reduce the rate of decline in the kidney's GFR over time. In the bardoxolone CKD study, approximately 90 percent of patients on drug experienced an increase in their GFR, and patients with more severe stage 4 CKD at baseline experienced an even greater (36 percent) increase in GFR (p<0.0001). Based on the results of this Phase II clinical trial, Reata has initiated a longer term, late stage trial of bardoxolone in patients with diabetes and advanced CKD.
	3.25.2009 - Reata Completes Financing and Expands Team to Capture Opportunity Created by Encouraging Clinical Data in Chronic Kidney Disease; Late Stage Trial Initiated in Patients with Advanced CKD
	IRVING, TX - March 25, 2009 -- Reata Pharmaceuticals, Inc. announced today that the company has made significant progress in advancing its lead project, bardoxolone methyl, for the treatment of chronic kidney disease (CKD). Based on encouraging results from a recently completed Phase 2a trial, the company has initiated a Phase 2b trial of this agent in patients with advanced chronic kidney disease (CKD) and Type 2 diabetes. To finance this trial, the company closed $32.0 million in the first tranche of a private financing round. Additionally, the company recently added Eric Grossman, a Nephrologist with significant drug development experience, to its team as the Vice President of Clinical Development and Medical Affairs.
	2.18.2009 - Reata's AIM Shows Promise for COPD in Study Published in Proceedings of the National Academy of Sciences
	Reata Pharmaceuticals, Inc. announced today that its Antioxidant Inflammation Modulator (AIM) CDDO-Im (also known as RTA 403) conferred protection to mice during chronic exposure to cigarette smoke, protecting against damage and related symptoms that cause chronic obstructive pulmonary disease (COPD) in a study published in the Proceedings of the National Academy of Sciences (January 6, 2009 issue) and featured in a “Research Highlights” review in Nature Reviews Drug Discovery (January 23, 2009 issue). The study was conducted by researchers at Johns Hopkins University, and Reata provided the AIM used in the study.

	10.28.2008 - Reata to Present at BIO Investor Forum
	Reata Pharmaceuticals, Inc. announces that its CEO, Warren Huff, will be presenting a company overview on Thursday, October 30, 2008 at the 7th Annual BIO Investor Forum at 11:30 a.m., Pacific Time. The event is being held at the Pacific Hotel in San Francisco, California.
	10.15.2008 - FDA Grants Orphan Drug Status to Reata's RTA 402 for Treatment of Pancreatic Cancer
	Reata Pharmaceuticals, Inc. announces that RTA 402 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. RTA 402 is currently being studied in a Phase 1/2 trial in patients with pancreatic cancer, and is also in Phase 2 development for chronic kidney disease.
	9.3.2008 - Reata to Present at Thomas Weisel Partners Healthcare Conference
	Reata Pharmaceuticals, Inc. announces that its Vice President of Finance, Jason Wilson, will be presenting a company overview on Wednesday, September 3, 2008 at the Thomas Weisel Partners Healthcare Conference at 9:45 a.m., Eastern Time. The event is being held at the Four Seasons Hotel in Boston, MA.
	7.28.2008 - Reata to Present at BMO Capital Markets Healthcare Conference
	Reata Pharmaceuticals, Inc. announces that its CEO, Warren Huff, will be presenting a company overview on Wednesday, August 6, 2008 at the BMO Capital Markets "Focus on Healthcare Conference" at 9:00 a.m., Eastern Time. The event is being held at the Milennium Broadway Hotel in New York, New York.
	6.18.2008 - Reata Expands Executive Team to Support Advancing Clinical Programs
	Reata Pharmaceuticals, Inc. announced a substantial expansion of its executive team to take advantage of opportunities from its advancing clinical and preclinical pipelines. Seasoned executives have been added to the team in the areas of clinical development, regulatory affairs, and business development.
	6.1.2008 - ASCO: First-In-Man Study of RTA 402 Yields Promising Results in Patients with Advanced Cancers
	Reata Pharmaceuticals, Inc. announced results from a first-in-man study of RTA 402 in patients with advanced cancers, presented in an oral session at the annual meeting of the American Society for Clinical Oncology. RTA 402 is the clinical lead from Reata's Antioxidant Inflammation Modulators (AIMs), a new and highly promising category of drugs for the treatment of cancer and inflammation. One of the study's Principal Investigators, Dr. David Hong from the University of Texas M. D. Anderson Cancer Center, presented data showing that RTA 402 had an excellent safety profile and provided a clinical benefit in a significant percentage of patients. Investigators also confirmed that the drug was active against its biological targets, NF-kappa B and STAT3. These pro-inflammatory transcription factors promote tumor growth, angiogenesis, invasion, metastasis, and resistance to therapy. Overall, RTA 402 showed a profile of disease control and tumor reduction comparable or superior to any recently approved targeted therapy in a Phase I patient population and a markedly superior side effect profile.
	5.27.2008 - Reata to Present at FBR Capital Markets Investor Conference in NYC on May 29
	Reata Pharmaceuticals, Inc. announces that its CEO, Warren Huff, will be presenting a company overview on Thursday, May 29, 2008 at the FBR Capital Markets 12th Annual Spring Investor Conference. This event is being held at the Grand Hyatt hotel in New York, New York. Mr. Huff's presentation is scheduled for 2:00 pm Eastern Time. The presentation will focus on Reata's two franchise technologies: its AIM platform of novel, broad-spectrum anti-inflammatory agents and its protein folding discovery platform. It will also highlight a number of upcoming Phase 2 data events with Reata's two lead compounds.
	5.22.2008 - 10 New Papers Published on Anti-Cancer Effects of Reata AIMs
	Reata Pharmaceuticals, Inc. announced the publication of 10 separate peer-reviewed papers supporting the use of its Antioxidant Inflammation Modulators (AIMs) in cancer patients. These papers reflect work conducted at leading academic institutions including Dartmouth Medical School, The Burnham Institute, and the Dana-Farber Cancer Institute. Collectively, they further elucidate the novel mechanism of action of the AIMs in cancer, demonstrate effects in a broad array of tumor types, and show consistent activity across multiple structural analogs.
	5.21.2008 - Phase 1 Cancer Results with RTA 402 Scheduled for Oral Presentation at 2008 ASCO
	Results of a Phase 1 clinical trial of RTA 402 in patients with advanced cancers was selected for an oral presentation at the 2008 annual meeting of the American Society of Clinical Oncologists.
	4.11.2008 - Updated Data on Reata's Two Clinical Candidates Presented at 2008 Annual Meeting of the American Association of Cancer Research
	Reata Pharmaceuticals, Inc. announced today the presentation of significant new preclinical data on its two clinical-stage compounds, berubicin hydrochloride (an anthracycline derivative formerly known as RTA 744) and RTA 402 (the lead agent in Reata’s portfolio of Antioxidant Inflammation Modulators, or AIMs, also known as CDDO-Me).
	2.8.2008 - Reata to Present at 2008 BIO CEO and Investor Conference on 2/11 at 2:00 pm
	IRVING, TX - February 8, 2008 - Reata Pharmaceuticals, Inc. announces that its CEO, Warren Huff, will be presenting a company overview on Monday, February 11, 2008 at the Biotechnology Industry Organization's CEO and Investor Conference at 2:00 p.m., Eastern Time. The presentation will include an update on the company's portfolio of clinical development programs as well as its best-in-class protein folding discovery platform.

	10.24.2007 - RTA 402 Phase 1 Results Presented at AACR-NCI-EORTC Conference; Exceptional Tolerability with Significant Anti-Cancer Activity
	10.18.2007 - Industry Leaders Select RTA 402 as Top 10 Most Promising New Cancer Drugs
	7.6.2007 - Reata Closed $25 Million Financing; Supports Phase 2 studies of lead programs
	6.28.2007 - RTA 402 Shown to Protect Animals from Toxicities of Standard Cancer Treatments; Results Presented at Major Conference
	5.15.2007 - Cancer Research Article Shows RTA 402 Inhibits STAT3, effective in breast cancer
	4.25.2007 - Triterpenoids Profiled in Nature Reviews Cancer

	11.15.2006 - RTA 402 Prevents Development of Lung Cancer
	11.10.2006 - Reata Announces Interim Results of Phase 1 Brain Tumor Trial; Complete Response Reported
	10.26.2006 - Reata Receives Orphan Drug Status for RTA 744
	8.4.2006 - Reata Announces Closing of $22.6 Million Financing to support advanced clinical development
	6.21.2006 - Reata to Present at Jefferies Life Sciences Conference June 27, 2006
	4.17.2006 - Reata Licenses Novel Class of Anti-Inflammatory Compounds; Potential in Many Therapeutic Areas
	4.6.2006 - RTA 402 Enters Clinical Trials; Oral Anticancer Drug has Unique Preclinical Profile
	4.5.2006 - RTA 402 Proven to Inhibit NF-?B Through Inhibition of IKK
	3.30.2006 - Reata to Present at BIO on April 12, 2006
	2.17.2006 - Reata Drug Prevents Liver Cancer; Results on Cover of Cancer Research

	11.14.2005 - Reata Programs Highlighted at EORTC-NCI-AAACR Conference
	11.4.2005 - Reata Drug Effective in Preventing Liver Cancer; Results Presented at AACR Conference
	11.3.2005 - Reata Announces Receipt of SBIR Grant for Discovery Platform
	10.12.2005 - Reata Announces RTA 401 Entering Clinical Development; CRADA Signed with NCI
	6.1.2005 - Reata Appoints Charles A. Sanders, M.D. to its Board of Directors
	5.10.2005 - Reata Announces Licensing of Novel Natural Products with Anticancer Potential
	5.5.2005 - Reata Announces RTA 744 Receives IND Approval; Name changed to Reata Pharmaceuticals, Inc.
	3.22.2005 - Synthetic Triterpenoids Induce Phase 2 Response; Link Shown Between Antiinflammatory and Antioxidant Activities

	11.11.2004 - Reata Announces Closing of $12.0 Million Financing
	11.1.2004 - Reata Announces Licensing of Novel Anticancer Compounds with Broad Clinical Potential

	9.16.2003 - Reata Announces Completion of In License Activities, Recruitment of Founding Scientists, and Financing Round